Fast Track Initiative portfolio firm Metagen Therapeutics starts Phase 1/2 trial of oral FMT drug MGT-006 in ulcerative colitis patients

  • Fast Track Initiative portfolio company Metagen Therapeutics launched a Phase 1/2 trial of MGT-006 for moderate ulcerative colitis in Japan, US.
  • MGT-006 is an oral fecal microbiota transplant drug candidate designed to enable FMT via capsules.
  • Trial is open-label, international; positioned as Japan’s first clinical trial of an FMT drug.
  • Program uses donor microbiota sourced from Metagen Therapeutics’ Tsuruoka stool donation facility in Yamagata.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fast Track Initiative Inc published the original content used to generate this news brief on June 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.